Can a simple shot keep breast cancer patients safe from infection?

NCT ID NCT07525869

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called pegfilgrastim (Neulasta) can prevent a dangerous drop in white blood cells and fever (febrile neutropenia) in women with triple-negative breast cancer. The 40 participants receive the drug after each round of AC chemotherapy, which follows earlier chemo with paclitaxel and carboplatin. The goal is to see if this approach reduces infections and hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pegfilgrastim (Neulasta)
What this could lead to: If it works, this could provide evidence that pegfilgrastim safely prevents serious infections during chemotherapy for triple-negative breast cancer patients.
What could go wrong: This is a small, early-phase study with only 40 participants and no comparison group, so results may not be conclusive or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Gangnam Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 06273, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.